- Home
- RAND vs LSB Comparison
RAND vs LSB Comparison
Compare RAND & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- LSB
- Stock Information
- Founded
- RAND 1969
- LSB 2002
- Country
- RAND United States
- LSB China
- Employees
- RAND N/A
- LSB N/A
- Industry
- RAND Finance: Consumer Services
- LSB
- Sector
- RAND Finance
- LSB
- Exchange
- RAND Nasdaq
- LSB NYSE
- Market Cap
- RAND 47.5M
- LSB 41.2M
- IPO Year
- RAND N/A
- LSB N/A
- Fundamental
- Price
- RAND $16.40
- LSB $2.60
- Analyst Decision
- RAND
- LSB
- Analyst Count
- RAND 0
- LSB 0
- Target Price
- RAND N/A
- LSB N/A
- AVG Volume (30 Days)
- RAND 2.2K
- LSB 73.7K
- Earning Date
- RAND 11-06-2024
- LSB 11-29-2024
- Dividend Yield
- RAND 7.07%
- LSB N/A
- EPS Growth
- RAND 123.39
- LSB N/A
- EPS
- RAND 4.98
- LSB N/A
- Revenue
- RAND $8,351,941.00
- LSB $79,415,311.00
- Revenue This Year
- RAND N/A
- LSB $39.33
- Revenue Next Year
- RAND N/A
- LSB $75.61
- P/E Ratio
- RAND $3.30
- LSB N/A
- Revenue Growth
- RAND 16.96
- LSB N/A
- 52 Week Low
- RAND $12.50
- LSB $1.88
- 52 Week High
- RAND $19.60
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- RAND 50.67
- LSB 43.52
- Support Level
- RAND $16.05
- LSB $2.36
- Resistance Level
- RAND $16.46
- LSB $2.79
- Average True Range (ATR)
- RAND 0.11
- LSB 0.48
- MACD
- RAND 0.04
- LSB 0.12
- Stochastic Oscillator
- RAND 75.47
- LSB 46.15
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.